Snyder Mark Howard Insider Trades

Insider Trading History

Track insider trading activity for Snyder Mark Howard. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $979k 14,022 shares
Last Trade
Feb 23, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$495k 7,011 shares
$70.64
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.59M 51,392 shares
Last Trade
Feb 23, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$495k 7,011 shares
$70.64
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.32M 47,610 shares
Last Trade
Feb 23, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$267k 3,782 shares
$70.64
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.3M 47,257 shares
Last Trade
Feb 20, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$378k 5,332 shares
$70.98
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $1.12M 15,995 shares
Last Trade
Feb 20, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$378k 5,332 shares
$70.98
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.1M 44,381 shares
Last Trade
Feb 20, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$204k 2,876 shares
$70.98
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $335k 4,796 shares
Last Trade
Feb 16, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$1.34M 16,812 shares
$79.44
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.93M 41,925 shares
Last Trade
Feb 16, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$720k 9,068 shares
$79.44
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.38M 48,406 shares
Last Trade
Feb 16, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$1.34M 16,812 shares
$79.44
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $3.15M 45,127 shares
Last Trade
Feb 09, 2026 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$6.28M 78,087 shares
$80.48
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.39M 34,181 shares
Last Trade
Jan 03, 2026 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$298k 4,243 shares
$70.31
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $0 0 shares
Last Trade
Jan 03, 2026 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$535k 7,611 shares
$70.31
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.68M 38,424 shares
Last Trade
Jan 03, 2026 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$535k 7,611 shares
$70.31
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.34M 33,524 shares
Last Trade
Jun 12, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$275k 5,035 shares
$54.54
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $1.05M 15,102 shares
Last Trade
Jun 12, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$275k 5,035 shares
$54.54
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.15M 30,813 shares
Last Trade
Jun 12, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$148k 2,711 shares
$54.54
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $1.99M 28,489 shares
Last Trade
Feb 23, 2025 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$218k 3,775 shares
$57.75
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $1.47M 21,033 shares
Last Trade
Feb 23, 2025 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$405k 7,012 shares
$57.75
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $2.25M 32,264 shares
Last Trade
Feb 23, 2025 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$405k 7,012 shares
$57.75
$69.82
Halozyme Therapeutics
Halozyme Therapeutics HALO
Svp, CHIEF LEGAL OFFICER
Holding Value $1.58M 22,603 shares
Last Trade
Feb 20, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.3M 22,603 shares
$57.44
$69.82

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up